Please assess the completion status of the following clinical trial:

Trial Title: Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients at least 12 years of age~* Male and female; female subjects of childbearing potential must be willing to use birth control~* Pre-bronchodilator FEV1 of 40-90% predicted normal~* Reversibility FEV1 of at least 12% and 200mL~* Current asthma therapy includes inhaled corticosteroid use for at least 12 weeks prior to first visit~Exclusion Criteria:~* History of life-threatening asthma during last 10 years~* Respiratory infection or oral candidiasis~* Asthma exacerbation requiring oral corticosteroids or that required overnight hospitalisation requiring additional asthma treatment~* Uncontrolled disease or clinical abnormality~* Allergies to study drugs or the excipients~* Taking another investigational medication or prohibited medication~* Night shift workers~* Current smokers or subjects with a smoking history of at least 10 pack years

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone furoate/Vilanterol (GW642444) (Type: EXPERIMENTAL): Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
- Fluticasone Furoate (Type: EXPERIMENTAL): Fluticasone furoate inhalation powder once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo inhalation powder once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).